Abstract
Uveal melanoma (UM) is the most common primary intraocular tumor. Despite successful treatment of the primary tumor, 50% of patients develop distant metastases. To date, there are no clear standards for choosing the first line of therapy for metastatic UM. The article presents a retrospective analysis of the effectiveness and safety of first-line therapy in 125 patients with metastatic UM who applied to the N.N. Blokhin National Medical Research Center of Oncology in the period from 2020 to 2023.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
